RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 907-913

  Deane, Rashid ^a   Yan, Shi Du ^b   Submamaryan, Ram Kumar ^c   LaRue, Barbara ^a   Jovanovic, Suzana ^c   Hogg, Elizabeth ^c   Welch, Deborah ^a   Manness, Lawrence ^a   Lin, Chang ^b   Yu, Jin ^d   Zhu, Hong ^d   Ghiso, Jorge ^e   Frangione, Blas ^e   Stern, Alan ^b   Schmidt, Ann Marie ^b   Armstrong, Don L ^a   Arnold, Bernd ^f   Liliensiek, Birgit ^f   Nawroth, Peter ^f   Hofman, Florence ^c   Kindy, Mark ^d   Stern, David ^b,g   Zlokovic, Berislav ^a   more..

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; CYTOKINE; ENDOTHELIN 1; LIGAND;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; CELL DAMAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMENTIA; INFLAMMATION; LIGAND BINDING; MOUSE; NERVE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STRESS; VASCULARIZATION; VASOCONSTRICTION;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR CIRCULATION; CYTOKINES; ENDOTHELIN-1; HUMANS; MICE; MICE, TRANSGENIC; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN TRANSPORT; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; RECEPTORS, IMMUNOLOGIC;

ANIMALIA;

EID: 0037703255     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm890     Document Type: Article

References (45)

1. Selkoe, D.J. Clearing the brain's amyloid cobwebs, Neuron 32, 177-180 (2001).
2. Yan, S.D. et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691 (1996).
3. Thomas, T., Thomas, G., McLendo, C., Sutton, T. & Mullan, M, β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 115-118 (1996).
4. 1-40 peptide from brain by low-density lipoprotein receptor-related protein-1 at the blood brain barrier J. Clin. Invest 106, 1489-1499 (2000).
5. Zlokovic, B.V. et al. Clearance of amyloid-β-peptide from brain: transport or metabolism? Nat. Med. 6, 718-719 (2000).
6. 40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J. Drug Targeting 10, 359-368 (2002).
7. 40 efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295, 2264-2267 (2002).
8. DeMattos, R.B. et al. Plaque-associated disruption of CSF and plasma amyloid-βequilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81, 229-236 (2002).
9. Mackic, J.B. et al. Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc. Pharmacol. 38, 303-313 (2002).
10. Zlokovic, B.V. et al. Blood-brain barrier transport of circulating Alzheimer's amyloid-β Biochem. Biophys. Res. Commun. 197, 1034-1040 (1993).
11. Maness, L.M., Banks, W.A., Podlisny, M.B., Selkoe, D.J. & Kastin, A.J. Passage of human amyloid-β protein 1-40 across the murine blood-brain barrier. Life Sci. 55, 1643-1650 (1994).
12. 1-40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 7, 2607-2611 (1996).
13. Martel, C.L. et al. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid-β in guinea pigs. Neurosci. Lett. 206, 157-160 (1996).
14. Zlokovic, B.V, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid-β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA 93, 4229-4236 (1996).
15. Martel, C.L. et al. Isoform-specific effects of apolipoproteins E2, E3, E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β. J. Neurochem. 69, 1995-2004 (1997).
16. Mackic, J.B. et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid-β peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 70, 210-215 (1998).
17. Poduslo, J.F., Curran, G.L., Sanyal, B. & Selkoe, D.J. Receptor-mediated transport of human amyloid-β1-40 and 1-42 at the blood-brain barrier. Neurobiol. Dis. 6, 190-199 (1999)
18. Wengenack, T.M., Curran, G.L. & Poduslo, J.F. Targeting Alzheimer amyloid plaques in vivo. Nat. Biotech. 18, 868-872 (2000).
19. Ghersi-Egea, J.F. et al. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67, 880-883 (1996).
20. Monro, O.R. et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol. Aging 23, 405-412 (2002).
21. Sigurdsson, E.M. et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. PathoL 159, 439-447 (2001).
22. Matsuoka, Y. et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23, 29-33 (2003).
23. Carro, E. et al. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat. Med. 8, 1390-1397 (2002).
24. Hofmann, M.A. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901 (1999).
25. Yan, S.D. et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6, 643-651 (2000).
26. Mackic, J.B. et al. Human blood-brain barrier receptors for Alzheimer's amyloid-β 1-40: asymmetrical binding, endocytosis and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102, 734-743 (1998).
27. Kawarabayashi, T. et al. Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372-381 (2001).
28. DeMattos, R.B. et al. Potential role of endogenous and exogenous Aβ binding molecules in Aβ clearance and metabolism. in Aβ Metabolism in Alzheimer's Disease (ed. Saido, T.) 123-139 (Landes Bioscience, Georgetown, Texas, 2003).
29. Hsiao, K. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
30. Hsia, A. et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA 96, 3228-3233 (1999).
31. Sakaguchi, T. et al. Central role for RAGE-dependent neointimal expansion in arterial stenosis. J. Clin. Invest. 111, 959-972 (2003)
32. Wyss-Coray, T. et al. TGF-β-1 promotes microglial amyloid clearance and reduces plaque burden in transgenic mice. Nat. Med. 7, 612-618 (2001).
33. Helme, R., Chen, H. & Khalil Z. Mechanisms underlying the vascular activity of Aβ(25-35) at the level of skin microvasculature. Brain Res. 736, 206-216 (1996).
34. Holtzman, D. et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann. Neurol. 47, 739-747 (2000).
35. Iadecola, C. et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat, Neurosci. 2, 157-161 (1999).
36. Takashi R.J. et al. Intraneuronal Alzheimer's Aβ42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869-1879 (2002).
37. Paris, D. et al. Soluble β-amyloid peptide mediate vasoactivity via activation of a proinflammatory pathway. Neurobiol. Aging 21, 183-197 (2000).
38. Niwa, K. et al. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. USA 97, 9735-9740 (2000).
39. Estrada, C., Gomez, C. & Martin, C. Effects of TNF-α on the production of vasoactive substances by cerebral endothelial and smooth muscle cells in culture. J. Cereb. Blood Flow Metab. 15, 920-928 (1995).
40. Tureen J. Effect of recombinant human tumor necrosis factor α on cerebral oxygen uptake, cerebrospinal fluid lactate, and cerebral blood flow in the rabbit: role of nitric oxide. J. Clin. Invest. 95, 1086-1091 (1995).
41. Quehenberger P. et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49, 1561-1570 (2000).
42. Wautier, J-L. et al. Advanced glycation endproducts (AGEs) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 91, 7742-7746 (1994).
43. Wautier, J-L. et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation endproducts blocks hyperpermeability. J. Clin. Invest. 97, 238-243 (1996).
44. Niwa, K., Kazama, K., Younkin, S.G., Carlson, G.A. & Iadecola, C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9, 61-68 (2002).
45. 14C]iodontipyrine injection and final arterial heart blood sampling. J. Cereb. Blood Flow Metab. 20, 10-14 (2000).